Latest Regulatory News

ACDC Metals has reported strong scoping study results for its Goschen Central heavy mineral sands and rare earth project, highlighting a promising 14-year mine life and a strategic retention licence application to support ongoing development.

Zeotech Limited’s latest quarterly report highlights a robust Preliminary Feasibility Study for its AusPozz™ low-carbon cement project, alongside successful commercial concrete trials and promising methane reduction technology.

Neurizon Therapeutics has made significant strides in developing its lead ALS drug candidate NUZ-001, unveiling a new liquid formulation and submitting a key regulatory response to the FDA. Clinical and preclinical data bolster hopes for broader neurodegenerative applications.

Vintage Energy reported a modest decline in quarterly sales revenue and production but strengthened its cash position through a fully subscribed capital raising and strategic asset sale agreement. The company also initiated a promising feasibility study on a CO2 liquefaction plant at Nangwarry.

Acrux Limited reports promising revenue growth driven by new topical generic launches in the US and secures crucial RDTI funding, marking a strategic shift under new CEO John Warmbrunn.

Lakes Blue Energy has secured $6.5 million in new capital and is set to begin drilling the Wombat-5 gas well, targeting near-term supply to Victoria’s east coast market. Meanwhile, its Nangwarry carbon dioxide project moves forward with a fully funded feasibility study.

Felix Gold is advancing its Treasure Creek Project in Alaska, aiming for the first domestic antimony concentrate production in over 30 years by late 2025 or early 2026, supported by strong government engagement and solid finances.

Actinogen Medical has reached a key milestone in its XanaMIA phase 2b/3 Alzheimer’s trial with over 100 participants enrolled, setting the stage for an interim analysis in January 2026. The company also secured a $13.8 million non-dilutive R&D funding facility to support ongoing development.

Vitrafy Life Sciences reported robust progress in Q4 FY2025, advancing its cryopreservation technology and commercial partnerships while preparing for a pivotal product launch in FY2026.

Avecho Biotechnology has ramped up recruitment in its pivotal Phase III insomnia trial and is advancing plans for regulatory approval and commercialization of its TPM®-enhanced CBD capsule, aiming to be the first over-the-counter CBD insomnia treatment in Australia.

Recharge Metals Limited has made significant progress in its uranium and copper projects, advancing permitting and drill planning in Montana while identifying promising sulphide targets in Western Australia.

Peel Mining has completed key drilling and testwork at its Wagga Tank site while identifying promising gold targets at Nombinnie, setting the stage for expanded exploration.